within Pharmacolibrary.Drugs.ATC.L;

model L04AD02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.0006333333333333333,
    adminDuration  = 600,
    adminMass      = 0.005,
    adminCount     = 1,
    Vd             = 0.00161,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.018666666666666668,
    Tlag           = 2400
  );

  annotation(Documentation(
    info ="<html><body><p>Tacrolimus is an immunosuppressant macrolide used primarily to prevent organ transplant rejection and to treat certain autoimmune diseases. It acts by inhibiting calcineurin, thus suppressing T-lymphocyte activation. It is approved and remains widely used in clinical practice, particularly for kidney, liver, and heart transplant recipients.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic model parameters reported for adult kidney transplant recipients following oral administration in the early post-transplant period, population containing both sexes.</p><h4>References</h4><ol><li>R Venkataramanan, A Swaminathan, T Prasad, A Jain, S Zuckerman, V Warty, J McMichael, J Lever, G Burckart, T Starzl,Clinical pharmacokinetics of tacrolimus.,Clinical pharmacokinetics,1995<a href='https://pubmed.ncbi.nlm.nih.gov/8787947/'>https://pubmed.ncbi.nlm.nih.gov/8787947/</a></li><li>Christine E Staatz, Susan E Tett,Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.,Clinical pharmacokinetics,2004<a href='https://pubmed.ncbi.nlm.nih.gov/15244495/'>https://pubmed.ncbi.nlm.nih.gov/15244495/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L04AD02;
